Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

@article{Schlenker2017ChimericPR,
  title={Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.},
  author={Ramona Schlenker and Luis Felipe Olgu{\'i}n-Contreras and Matthias S Leisegang and Julia Schnappinger and Anja Disovic and Svenja R{\"u}hland and Peter Jon Nelson and Heinrich Leonhardt and Hartmann Harz and Susanne Wilde and Dolores J. Schendel and Wolfgang Uckert and Gerald Willimsky and Elfriede Noessner},
  journal={Cancer research},
  year={2017},
  volume={77 13},
  pages={
          3577-3590
        }
}
Inherent intermediate- to low-affinity T-cell receptors (TCR) that develop during the natural course of immune responses may not allow sufficient activation for tumor elimination, making the majority of T cells suboptimal for adoptive T-cell therapy (ATT). TCR affinity enhancement has been implemented to provide stronger T-cell activity but carries the risk of creating undesired cross-reactivity leading to potential serious adverse effects in clinical application. We demonstrate here that… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 52 REFERENCES

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

JuneCH. TheCD28 family: a T-cell rheostat for therapeutic control of T-cell activation

JL Riley
  • Blood
  • 2005
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL